NCT00554983View on ClinicalTrials.gov

Efficacy and Safety From a Recombinant Folding Variant of Bet v 1

PHASE3CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

May 31, 2012

Conditions
Allergy
Interventions
BIOLOGICAL

recombinant birch pollen allergen

subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram

BIOLOGICAL

placebo

subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram

Trial Locations (1)

21465

Allergopharma GmbH & Co. KG, Reinbek

All Listed Sponsors
lead

Allergopharma GmbH & Co. KG

INDUSTRY

NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 | Biotech Hunter | Biotech Hunter